PL3250185T3 - Oftalmiczna kompozycja zawiesinowa - Google Patents

Oftalmiczna kompozycja zawiesinowa

Info

Publication number
PL3250185T3
PL3250185T3 PL16704744T PL16704744T PL3250185T3 PL 3250185 T3 PL3250185 T3 PL 3250185T3 PL 16704744 T PL16704744 T PL 16704744T PL 16704744 T PL16704744 T PL 16704744T PL 3250185 T3 PL3250185 T3 PL 3250185T3
Authority
PL
Poland
Prior art keywords
suspension composition
ophthalmic suspension
ophthalmic
composition
suspension
Prior art date
Application number
PL16704744T
Other languages
English (en)
Inventor
Mohannad Shawer
Eric Phillips
Martin J. Coffey
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55359733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3250185(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of PL3250185T3 publication Critical patent/PL3250185T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL16704744T 2015-01-26 2016-01-26 Oftalmiczna kompozycja zawiesinowa PL3250185T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562107696P 2015-01-26 2015-01-26
PCT/US2016/014872 WO2016123079A1 (en) 2015-01-26 2016-01-26 Ophthalmic suspension composition
EP16704744.8A EP3250185B1 (en) 2015-01-26 2016-01-26 Ophthalmic suspension composition

Publications (1)

Publication Number Publication Date
PL3250185T3 true PL3250185T3 (pl) 2019-05-31

Family

ID=55359733

Family Applications (4)

Application Number Title Priority Date Filing Date
PL18209003T PL3470059T3 (pl) 2015-01-26 2016-01-26 Kompozycja zawiesiny okulistycznej
PL20166312.7T PL3721868T3 (pl) 2015-01-26 2016-01-26 Oftalmiczna kompozycja zawiesinowa
PL16704744T PL3250185T3 (pl) 2015-01-26 2016-01-26 Oftalmiczna kompozycja zawiesinowa
PL22175139.9T PL4082531T3 (pl) 2015-01-26 2016-01-26 Oftalmiczna kompozycja zawiesinowa

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL18209003T PL3470059T3 (pl) 2015-01-26 2016-01-26 Kompozycja zawiesiny okulistycznej
PL20166312.7T PL3721868T3 (pl) 2015-01-26 2016-01-26 Oftalmiczna kompozycja zawiesinowa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL22175139.9T PL4082531T3 (pl) 2015-01-26 2016-01-26 Oftalmiczna kompozycja zawiesinowa

Country Status (14)

Country Link
US (3) US10596107B2 (pl)
EP (5) EP4082531B1 (pl)
JP (1) JP2018507252A (pl)
KR (1) KR102538370B1 (pl)
CN (1) CN107427464B (pl)
AU (3) AU2016211745A1 (pl)
BR (1) BR112017016016B1 (pl)
CA (1) CA2975106A1 (pl)
ES (4) ES2704125T3 (pl)
HU (3) HUE059639T2 (pl)
MX (1) MX2017009699A (pl)
PL (4) PL3470059T3 (pl)
PT (2) PT4082531T (pl)
WO (1) WO2016123079A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE059639T2 (hu) 2015-01-26 2022-12-28 Bausch & Lomb Szemészeti szuszpenzió kompozíció
CA3001955C (en) 2015-10-16 2023-11-28 Sun Pharma Advanced Research Company Limited Ophthalmic solution of difluprednate
LT3245988T (lt) 2016-05-18 2024-02-12 Sonikure Holdings Limited Ultragarsu pagerinto transsklerinio vaistų pristatymo sistema
WO2019036483A1 (en) 2017-08-15 2019-02-21 Nephron Pharmaceuticals Corporation AQUEOUS NEBULIZATION COMPOSITION
WO2020061249A2 (en) * 2018-09-21 2020-03-26 Ps Therapies Ltd. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
EP4013423A4 (en) * 2019-08-18 2023-08-16 IVIEW Therapeutics, Inc. IN SITU GEL-FORMING OPHTHALMIC FORMULATIONS WITH DIFLUPREDNATE
KR102271247B1 (ko) * 2020-11-04 2021-06-30 삼천당제약주식회사 안과용 현탁액 조성물의 제조방법
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4540930A (en) 1983-09-12 1985-09-10 Wisconsin Alumni Research Foundation Plywheel-powered mobile X-ray apparatus
US4615697A (en) 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IE63392B1 (en) 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
US5124154A (en) 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
CA2134376C (en) 1993-12-20 2001-10-23 Haresh G. Bhagat Combinations of polymers for use in physiological tear compositions
US5556848A (en) * 1993-12-27 1996-09-17 Senju Pharmaceutical Co., Ltd. Ophthalmic suspension containing diflupredonate
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
CA2839847C (en) 2003-06-13 2016-03-15 Masood A. Chowhan Ophthalmic compositions containing a synergistic combination of two polymers
US20050197303A1 (en) 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050182039A1 (en) 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US7919483B2 (en) 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20120028947A1 (en) 2005-11-14 2012-02-02 Erning Xia Ophthalmic Compositions
WO2007058935A2 (en) 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20100234336A1 (en) 2005-11-14 2010-09-16 Erning Xia Ophthalmic Compositions
US8846770B2 (en) * 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
CN101966143A (zh) 2009-07-28 2011-02-09 胡容峰 加替沙星温度及pH敏感眼用凝胶的制备与应用
DK2506831T3 (da) 2009-12-03 2013-12-16 Alcon Res Ltd Carboxyvinylpolymerholdige nanopartikelsuspensioner
AU2012312816A1 (en) 2011-09-22 2014-04-24 Bausch & Lomb Incorporated Ophthalmic gel compositions
WO2014035451A1 (en) 2012-08-31 2014-03-06 Bausch & Lomb Incorporated Ophthalmic compositions with wax esters
EP2844295A1 (en) 2012-05-03 2015-03-11 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
MX361886B (es) 2012-05-08 2018-12-18 Nicox Ophthalmics Inc Preparaciones de agentes terapéuticos hidrófobos, métodos de elaboración y uso de los mismos.
US8765725B2 (en) * 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2848243B1 (en) * 2012-05-11 2023-07-12 Activus Pharma Co., Ltd. Organic compound nanopowder, production method therefor, and suspension
US20150190407A1 (en) 2014-01-07 2015-07-09 Insite Vision Incorporated Methods for treatment of postoperative inflammation with reduced intraocular pressure
NZ728136A (en) 2014-07-11 2017-10-27 Fujifilm Corp Method for producing aqueous ophthalmic composition, and aqueous ophthalmic composition
CN106535943A (zh) 2014-07-11 2017-03-22 富士胶片株式会社 眼科用水性组合物
ES2951202T3 (es) 2014-07-28 2023-10-19 Sun Pharma Advanced Res Co Ltd Método para aumentar la biodisponibilidad y/o prolongar la acción oftálmica de un fármaco
HUE059639T2 (hu) 2015-01-26 2022-12-28 Bausch & Lomb Szemészeti szuszpenzió kompozíció

Also Published As

Publication number Publication date
JP2018507252A (ja) 2018-03-15
HUE041945T2 (hu) 2019-06-28
EP3470059B1 (en) 2020-04-01
ES2966595T3 (es) 2024-04-23
PT3721868T (pt) 2022-08-12
EP3470059A1 (en) 2019-04-17
AU2021203027A1 (en) 2021-06-10
US10596107B2 (en) 2020-03-24
AU2023248145A1 (en) 2023-11-02
AU2016211745A1 (en) 2017-08-31
US20200214977A1 (en) 2020-07-09
EP3250185B1 (en) 2018-12-05
ES2924645T3 (es) 2022-10-10
CA2975106A1 (en) 2016-08-04
EP4268850A1 (en) 2023-11-01
US11534395B2 (en) 2022-12-27
EP3721868A1 (en) 2020-10-14
BR112017016016A2 (pt) 2018-03-20
PL3721868T3 (pl) 2022-11-07
ES2704125T3 (es) 2019-03-14
EP4082531B1 (en) 2023-10-11
PT4082531T (pt) 2023-12-14
US20230140895A1 (en) 2023-05-11
US20160213609A1 (en) 2016-07-28
MX2017009699A (es) 2017-10-23
KR102538370B1 (ko) 2023-06-01
CN107427464B (zh) 2022-04-05
EP3250185A1 (en) 2017-12-06
HUE048564T2 (hu) 2020-08-28
CN107427464A (zh) 2017-12-01
EP3721868B1 (en) 2022-06-01
WO2016123079A1 (en) 2016-08-04
PL4082531T3 (pl) 2024-04-08
KR20170105610A (ko) 2017-09-19
HUE059639T2 (hu) 2022-12-28
ES2787039T3 (es) 2020-10-14
PL3470059T3 (pl) 2020-11-30
AU2021203027B2 (en) 2023-07-13
BR112017016016B1 (pt) 2023-12-19
EP4082531A1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
IL249643A0 (en) Eye preparation
HK1244689A1 (zh) 水性眼科組合物
TWI563312B (en) Eyeglasses
HUE059639T2 (hu) Szemészeti szuszpenzió kompozíció
PL3373973T3 (pl) Kompozycje do oczu
GB2556619B (en) Suspension compositions
TWI563311B (en) Eyeglasses
SG11201707117SA (en) Ophthalmic composition
GB201619525D0 (en) Ophthalmic composition
GB2570376B (en) Suspension compositions
PL3446682T3 (pl) Kompozycja okulistyczna
ZA201703701B (en) Ophthalmic composition
IL251590A0 (en) Ophthalmic preparations
GB2556252B (en) Suspension arrangement
PT3093169T (pt) Mecanismo de suspensão
PT3470059T (pt) Composição de suspensão oftálmica
GB201516201D0 (en) Suspension
AU201610412S (en) Sunglasses
GB201501337D0 (en) Suspension arrangement
GB201518525D0 (en) Spectacles
GB201511428D0 (en) Stabilizer
GB201514291D0 (en) Spectacles
GB201421941D0 (en) Suspension bridges
GB201421938D0 (en) Suspension bridges
GB201421944D0 (en) Suspension bridges